PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Showing 1 - 2 of 2 results
News || 3 min read
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
Press Release || 6 min read